Isis Receives $1M Milestone From Merck
Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Merck based on the initiation of clinical development of a compound discovered through a joint research collaboration.
Details about the clinical candidate were not disclosed.
Galapagos to Acquire Inpharmatica for as Much as $25.4M
Galapagos this week said it plans to acquire Inpharmatica, a UK-based drug discovery database company in a stock deal potentially worth €19.1 million ($25.4 million).
Galapagos said it estimates that Inpharmatica’s ongoing business is worth €6.5 million.
Inpharmatica will become part of Galapagos’ drug-discovery branch, BioFocus DPI, and will contribute its Admensa ADME services and Chematica chemoinformatics services to expand client services.
Under the terms of the agreement, Galapagos will issue up tp 2.2 million of its shares at €8.82 apiece — or around €19.1 million — which was the trading price over the 30 days before Dec. 5, the day the acquisition was announced. Galapagos said it will issue these shares “assuming that all three components” — milestones, cash on hand, and Inpharmatica’s worth as an ongoing business — “are fully delivered.”
Invitrogen Closes $26M Sentigen Acquisition
Invitrogen this week said it has closed its acquisition of Sentigen Holding.
The $25.9 million cash deal was announced in September.
Invitrogen paid $3.37 per share for the Phillipsburg, NJ-based company, which will become part of Invitrogen’s Discovery Sciences division, located in Madison, Wis.
With the acquisition, Invitrogen picks up Sentigen’s Tango assay system for protein-interaction analysis and GPCR screening and its assay ready cells that pare down the assay process, the company said.